Discovery & Development

The end of “mini me” medicine is over, says Andrew Parker, because we can do better when it comes to pediatric care.

What is the current state of pharma contract development and manufacturing?

Making cancer drugs cheaper and more effective – with a paper “coffee” filter.

What is the current state of pharma contract development and manufacturing?

Valarie Higgins discusses how clinical trials have evolved over the years and the key lessons she has learned while building her career in the industry.

mAbs are an important growth area for the biopharma industry – so we need more effective purification technologies.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

Streamlined workflows help scientists plot a course for painless peptide mapping

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.